Barry D Quart
CIK 1384243 · Chief Executive Officer · last filed 2026-06-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.25M
Companies
4
Total Filings
83
Lifetime Open-Market Net
-$15.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KNSA | Director | 15,345 | $77.88 | $1.20M | -$3.87M | 16 | 2026-06-02 |
| HRTX | Chief Executive Officer | 183,208 | $0.32 | $58.4K | -$7.45M | 29 | 2023-01-20 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | — | — | — | $0 | 5 | 2015-06-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | President and CEO | 2,500 | — | — | -$4.05M | 20 | 2012-06-20 |
Recent Filings · Page 6 of 9
83 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-11-21 | — | Buy (P) | +1,000,000 | $400.0K | |
| 2013-06-10 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-03 | — | Grant (A) | — | $0 | |
| 2012-06-29 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-20 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Disp (D) | −43,348 | -$1.39M | EDGAR |
| 2012-01-11 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-12-29 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Gift (G) | −10,000 | $0 | EDGAR |
| 2011-12-22 | SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-12-20 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | −10,000 | $0 | EDGAR |
| 2011-05-11 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | — | -$466.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.